Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
May 9 AMLX Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript
May 9 EHAB Enhabit challenged by hedge fund AREX Capital seeking seven board seats - report
May 9 NXL Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
May 9 AMLX Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
May 9 AMLX Amylyx Pharmaceuticals GAAP EPS of -$1.75 misses by $1.76, revenue of $88.64M misses by $9.71M
May 9 AMLX Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
May 9 ACAD ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript
May 9 ACAD ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation
May 8 EHAB Enhabit (EHAB) Beats Q1 Earnings Estimates
May 8 PRTA Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
May 8 EHAB Enhabit GAAP EPS of $0.01, revenue of $262.4M
May 8 ACAD Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
May 8 PRTA Prothena GAAP EPS of -$1.34 misses by $0.12, revenue of $0.05M misses by $2.12M
May 8 EHAB Enhabit concludes review of strategic alternatives
May 8 EHAB Enhabit Concludes Review of Strategic Alternatives
May 8 ACAD Acadia Pharma GAAP EPS of $0.10 beats by $0.05, revenue of $205.83M misses by $2.75M
May 8 EHAB Enhabit Reports First Quarter 2024 Financial Results
May 8 ACAD Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
May 8 PRTA Prothena Reports First Quarter 2024 Financial Results and Business Highlights
May 8 AMLX Amylyx Pharmaceuticals Q1 2024 Earnings Preview
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags